louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05320484: Clinical Pilates Exercises On Posture In Patients With Shoulder-Neck Posture Problem
Official title: The Effect Of Clinical Pilates Exercises On Posture In The Adult Patients With Shoulder-Neck Posture Problem: A Single-blind Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Posture
Exercise
Keywords: Posture
Head and Shoulder
Pilates Based Exercises
Lead sponsor: Sanko University
Sponsor class: OTHER
First posted: 2022-04-11
Enrollment: 39
Sex: ALL
Minimum age (years): 20
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study was designed to investigate the effect of clinic pilates exercise in adult patients whith shoulder- neck posture problem. 51 patients with forward head posture(FHP) and rounded shoulder posture(RSP) were included in this study and they were randomly divided into two groups as clinical pilates (group 1, n=26) and classical posture exercises (group 2, n=25). Patients' demographics were recorded. Deep neck fleksor muscle(DNFM) endurance was evaluated by pressure biofeedback unit (PBU). Head, neck and shoulder posture were evaluated with wall- tragus, wall-acromion, tragus-acromion and chin-sternal notch distance. Flexibility for shoulder region was evaluated with back scratch test. The patients were evaluated both before the study and 6 weeks later.

Detailed description: Fifty-one individuals aged between 20-55 years whose FHP and RSP problems were determined by lateral posture analysis were included in the study. However, a total of 12 individuals, 6 from each of the 2 groups, were excluded from the study because they could not complete the treatment sessions. The study was completed with 39 participants.Individuals aged between 20-60 years, whose FHP and RSP problems were determined by lateral posture analysis, were included in the study. Those with severe pain in the neck and shoulder girdle, scoliosis and neurological problems and those who had undergone any surgery in the relevant regions were not included in the study. The individuals included in the study were randomized by lot and divided into 2 groups. Group 1 was given clinical pilates exercises, and Group 2 was given a program consisting of classical posture exercises. The exercise programs of both groups were performed by the same physiotherapist, and pre- and post-exercise evaluations were made by a different physiotherapist.

Eligibility criteria: Inclusion Criteria:

* FHP and RSP problems were determined by lateral posture analysis

Exclusion Criteria:

* skoliosis

Primary outcomes:
measure: Distance Measurements
timeFrame: 6 week
measure: The DNFM endurance
timeFrame: 6 week
measure: Shoulder Region Flexibility
timeFrame: 6 week
Secondary outcomes:
Other outcomes:
Locations:
city: Gaziantep
country: Turkey
facility: SANKO University
state: Please Select
Study officials:
affiliation: Sanko University
name: Meltem uzun
role: STUDY_DIRECTOR
References:
Clinical trial NCT05564884: Neonatal SARS-CoV-2 Anti-spike Protein Receptor-binding Domain Antibodies at Delivery
Official title: The Association of Neonatal SARS-CoV-2 Anti-spike Protein Receptor-binding Domain Antibodies at Delivery With Infant COVID-19 Infection Under Age 6 Months: a Prospective Cohort Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: COVID-19
Lead sponsor: Rabin Medical Center
Sponsor class: OTHER
First posted: 2022-10-04
Enrollment: 58
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Mothers prior to transfer to the delivery room and followed at the Maternity and Infant Ward

Brief summary: To assess the association between neonatal SARS-CoV-2 antibody level at delivery and infant COVID-19 infection under age 6 months, and to identify predictive factors for neonatal antibody level at delivery.

Detailed description: This prospective observational study was conducted at the Rabin Medical Center, Israel. Mothers were enrolled from September 2021 to mid-February 2022, prior to transfer to the delivery room, and followed at the Maternity and Infant Ward. The study was approved by the institutional ethics committee (RMC- 0275-21). Written informed consent was obtained from the participating mothers. Inclusion criteria included maternal recipient of at least one dose of the BNT162b2 mRNA COVID-19 vaccine or prior microbiologically-confirmed natural COVID-19 infection. Exclusion criteria included (a) preterm birth at \<34 weeks gestation; (b) congenital or acquired immune deficiency, including recipient of biological agents during the prior year to enrolment.

Eligibility criteria: Inclusion Criteria:

included maternal recipient of at least one dose of the BNT162b2 mRNA COVID-19 vaccine or prior microbiologically-confirmed natural COVID-19 infection

Exclusion Criteria:

(a) preterm birth at \<34 weeks gestation; (b) congenital or acquired immune deficiency, including recipient of biological agents during the prior year to enrolment.

Primary outcomes:
measure: neonatal anti-spike antibody levels
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Petach Tikva
country: Israel
facility: Schneider Children's Medical Center
Study officials:
affiliation: Schneider children medical center
name: Liat Ashkenazi-Hoffnung
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00674284: Adrenal Exhaustion Syndrome in Critically Ill Patients Without Improvement
Official title: Change of Serum Cortisol Levels in Patients Without Improvement in Intensive Care Unit
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Survival
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2008-05-07
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All of the adult patients (age \>18 years) admitted to the intensive care units of the National Taiwan University Hospital between January 2005 and December 2006 were surveyed.

Brief summary: We study the relationship between patient outcomes and sequential changes of serum cortisol level.

Detailed description: Elevated corticosteroid level to meet physiologic needs during acute illness is a protective response for stress. This homeostasis is maintained by the hypothalamic-pituitary-adrenal (HPA) axis. However, inadequate response as corticosteroid insufficiency in critically ill patients is reported with increasing frequency, especially in severe sepsis and septic shock. Thus, corticosteroids could be beneficial for septic shock or severe acute illness.

Once considered as normal adrenal function, adrenal insufficiency may developed later with chronic critical illness as adrenal exhaustion syndrome. It is easily overlooked and is possible due to the chronic secretion of systemic cytokines or other HPA axis-suppressive substances. There is still no consensus how often adrenal function testing should be repeated, although a re-evaluation should be considered if clinical symptoms and signs suggest adrenal insufficiency or deteriorating clinical condition.

Eligibility criteria: Inclusion Criteria:

* age over 18
* ICU admission
* had two cortisol data

Exclusion Criteria:

* first cortisol data abnormal
* cortisol data not checked in ICU

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Chao-Chi Ho
Study officials:
affiliation: 1. Department of Internal Medicine, National Taiwan University Hospital
name: Chao-Chi Ho, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00199784: Hemodynamic Measurements During Cesarean Section With Spinal Anesthesia
Official title: Hemodynamic Measurements During Cesarean Section With Spinal Anesthesia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Healthy
Keywords: Hemodynamic
Hypotension
Spinal
Anesthesia
Healthy pregnant women for elective cesarean section
Lead sponsor: Oslo University Hospital
Sponsor class: OTHER
First posted: 2005-09-20
Enrollment: 80
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to determine the effect of low dose versus standard dose spinal anesthesia with and without intravenous phenylephrine-infusion on blood pressure, cardiac output and systemic vascular resistance.

Detailed description: Hypotension during cesarean section with spinal anesthesia is common. We compare low dose versus standard dose spinal anesthesia with and without intravenous phenylephrine-infusion.

Eligibility criteria: Inclusion Criteria:

* Healthy pregnant women for elective cesarean section

Exclusion Criteria

* Shorter than 160 or taller than 180 cm
* Pre-pregnant body mass index (BMI) over 32

Primary outcomes:
measure: Differences in cardiac output
measure: Blood pressure
measure: Systemic vascular resistance
Secondary outcomes:
measure: Nausea
measure: Fatigue
measure: Cardiovascular instability due to overdosing spinal anesthesia for cesarean section (CS)
Other outcomes:
Locations:
city: Oslo
country: Norway
facility: Rikshospitalet-Radiumhospitalet HF
Study officials:
affiliation: Oslo University Hospital
name: Eldrid Langesæter, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Langesaeter E, Rosseland LA, Stubhaug A. Continuous invasive blood pressure and cardiac output monitoring during cesarean delivery: a randomized, double-blind comparison of low-dose versus high-dose spinal anesthesia with intravenous phenylephrine or placebo infusion. Anesthesiology. 2008 Nov;109(5):856-63. doi: 10.1097/ALN.0b013e31818a401f.
Clinical trial NCT01005784: Fixed Versus Flexible Gonadotropin-releasing Hormone (GnRH) Antagonist Initiation
Official title: Fixed Versus Flexible GnRH Antagonist Initiation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Subfertility
Keywords: GnRH antagonists
Lead sponsor: Aristotle University Of Thessaloniki
Sponsor class: OTHER
First posted: 2009-11-01
Enrollment: 146
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 39
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a comparison of pregnancy achievement between two GnRH antagonist protocols which differ in the timing of GnRH antagonist initiation.


Eligibility criteria: Inclusion Criteria:

* \< 39 years of age
* BMI 18.5-29.9
* \<= 3 previous IVF cycles

Exclusion Criteria:

* PCOS
* Endometriosis

Primary outcomes:
measure: Luteinizing hormone rise
timeFrame: 3-14 days (duration of ovarian stimulation)
Secondary outcomes:
Other outcomes:
Locations:
city: Thessaloniki
country: Greece
facility: Unit for Human Reproduction
Study officials:
affiliation: Unit for Human Reproduction
name: Efstratios Kolibianakis
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kolibianakis EM, Venetis CA, Kalogeropoulou L, Papanikolaou E, Tarlatzis BC. Fixed versus flexible gonadotropin-releasing hormone antagonist administration in in vitro fertilization: a randomized controlled trial. Fertil Steril. 2011 Feb;95(2):558-62. doi: 10.1016/j.fertnstert.2010.05.052. Epub 2010 Jul 16.
Clinical trial NCT06992284: A Prognostic Study for Patients With Cardiovascular Disease in Niigata
Official title: A Prognostic Study Using Health Insurance Claim for Patients With Cardiovascular Disease in Niigata
Study type: OBSERVATIONAL
Overall status: ENROLLING_BY_INVITATION
Conditions: Cardiovascular Diseases
Heart Failure
Lead sponsor: Niigata University Medical & Dental Hospital
Sponsor class: OTHER
First posted: 2025-05-28
Enrollment: 8500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Eligible participants are individuals aged 18 or older who have been hospitalized in the cardiology department of a participating medical institution and are covered by Japan's National Health Insurance or the Late-stage Elderly Medical Care System

Brief summary: The goal of this observational study is to investigate the prognosis of cardiovascular disease in Niigata Prefecture.

Specifically, it aims to clarify the current status of medical treatment for cardiovascular disease patients in regional cities in Japan, where the population is aging.

With patient consent, the study will track long-term medical treatment progress using health insurance claim data recorded in Japan's unique social security system.


Eligibility criteria: Inclusion Criteria:

* Individuals aged 18 or older at the time of enrollment (regardless of gender).
* Individuals who have been hospitalized in the cardiology department of a participating medical institution.
* Individuals covered by Japan's National Health Insurance (NHI) or the Late-stage Elderly Medical Care System, which provide health coverage for self-employed individuals, retirees, and the elderly.

Exclusion Criteria:

* Individuals who are unable to obtain consent from themselves or their legally authorized representatives.

Primary outcomes:
measure: The rate of deterioration in care dependency levels as defined by Japan's Long-Term Care Insurance system
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Niigata
country: Japan
facility: Niigata University
Study officials:
References:
Clinical trial NCT04546984: Multiple Dose Safety, Tolerability, PK，PD and Food Effect Study of HEC96719 in Healthy Adult Subjects
Official title: A Randomized, Double-Blind, Placebo-Controlled Study of Ascending Multiple Doses to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics，and Randomized, Open-label，Crossover, Food Effect Study of HEC96719 in Healthy Chinese Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Nonalcoholic Steatohepatitis (NASH)
Lead sponsor: Sunshine Lake Pharma Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2020-09-14
Enrollment: 66
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The Safety, Tolerability, Pharmacokinetic, Pharmacodynamics and Food Effect Study of HEC96719 in Healthy Subjects


Eligibility criteria: Inclusion Criteria:

* Willing to participate in the study, able to understand and sign the informed consent, and able to complete the the study in accordance with the requirements of the study.
* Female subjects who are not pregnant or lactating and male subjects whose female partners are fertile shall voluntarily take effective contraceptive measures from the date of signing the informed consent form to 3 months after the medication.
* When signing the informed consent, 18 years old ≤the age≤45 years old(including the critical value), gender is not limited.
* Male body weight ≥50kg, female body weight ≥45kg, and body mass index (BMI) in the range of 18-28 kg/m2 (including the critical value).
* No clinical significance of vital signs, physical examination, laboratory examination, electrocardiogram, ultrasound abdomen and chest X-ray (posterior and anterior) results.

Exclusion Criteria:

* Positive for Viral hepatitis (including hepatitis B and C), HIV and syphilis.
* Those who are known to have allergy history or allergy constitution to the test preparation and any of its components or related preparations.
* Consume foods or beverages containing caffeine, xanthine, alcohol, and grapefruit within 48 hours prior to initial dosing.
* Positive results from urine drug screen test.
* Donate blood or lose blood 400 mL or more within 1 month prior to initial dosing.
* Subjects who plan to receive or have had organ transplants.
* Subjects considered by the investigator to have other factors unsuitable for participation in this study.

Primary outcomes:
measure: Safety and Tolerability of HEC96719 by Assessment of the Number of Adverse Events
timeFrame: up to 17 days
Secondary outcomes:
measure: Cmax
timeFrame: up to 96 hours
measure: AUC
timeFrame: up to 96 hours
measure: Tmax
timeFrame: up to 96 hours
measure: T1/2
timeFrame: up to 96 hours
Other outcomes:
Locations:
city: Shanghai
country: China
facility: The Shanghai xuhui district central hospital
state: Shanghai
Study officials:
References:
Clinical trial NCT04790084: Three-dimensional Choroidal Vascularity Index in Common Fundus Diseases
Official title: Changes of Three-dimensional Choroidal Vascular Index by Optical Coherence Tomography in Common Fundus Diseases
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Choroid
Keywords: choroidal vascularity index
fundus disease
choroidal blood flow
Lead sponsor: Renmin Hospital of Wuhan University
Sponsor class: OTHER
First posted: 2021-03-10
Enrollment: 300
Sex: ALL
Minimum age (years): 10
Maximum age (years): 75
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Chinese

Brief summary: Explore the changes of choroidal blood perfusion in common fundus diseases by three-dimensional choroidal vascularity index, an optical coherence tomography (OCT) parameter.

Detailed description: Compared with the choroidal vascularity index on a single OCT image, the three-dimensional choroidal vascularity index can evaluate the choroidal changes of chorioretinal diseases as a whole. In this study, the choroidal changes of patients with common fundus diseases were systematically evaluated by collecting OCT and optical coherence tomography angiography (OCTA) images of patients with common fundus diseases, especially in healthy people, myopic people and patients with central serous chorioretinopathy.

Eligibility criteria: 1. Healthy participants (1) Inclusion Criteria: 1) without systemic diseases such as diabetes and hypertension 2) best corrected visual acuity BCVA ≥ 1.0 3) aged 18 years or older (2) Exclusion criteria: 1) equivalent spherical refraction between -3 diopters and + 1.0 diopters 2) any visible lesions in the retina, optic nerve, or choroid 3) history of refractive or intraocular surgery
2. Myopia group (1) Inclusion Criteria: 1) equivalent spherical refraction greater than -0.25 diopters 2) without systemic diseases such as diabetes and hypertension 3) Best corrected visual acuity (BCVA) ≥ 1.0 4) aged 10 years or older (2) Exclusion criteria: 1) history of refractive or intraocular surgery 2) history of laser therapy 3) other systemic diseases that may affect the choroid
3. Central serous chorioretinopathy (CSC) group (1) Inclusion Criteria: 1) a diagnosis of CSC (2) Exclusion criteria: 1) high myopia or hyperopia (greater than 26 or +3 diopters of refractive error) 3) other systemic diseases that may affect the choroid 4) any other associated retinal pathology 5) history of refractive or intraocular surgery

Primary outcomes:
measure: Three-dimensional choroidal vascularity index
timeFrame: baseline, pre-intervention
Secondary outcomes:
measure: Choriocapillaris flow deficits%
timeFrame: baseline, pre-intervention
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Renmin Hospital of Wuhan University
state: Hubei
Study officials:
References:
Clinical trial NCT05286684: Feasibility of Exosome Analysis in Cerebrospinal Fluid During the Diagnostic Workup of Metastatic Meningitis (Exo-LCR)
Official title: Feasibility of Exosome Analysis in Cerebrospinal Fluid During the Diagnostic Workup of Metastatic Meningitis from Breast Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Breast Cancer
Keywords: leptomeningeal metastases
proteomic profile
cerebrospinal fluid
cytology analysis
Lead sponsor: Centre Oscar Lambret
Sponsor class: OTHER
First posted: 2022-03-18
Enrollment: 7
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The investigators are interested in one of the most frequent tumor types causing leptomeningeal metastasis in order to investigate whether a profile can be established by a high-throughput clinical proteomic approach. All the data acquired will allow a tailored and promising approach to improve the knowledge of metastatic tumor meningitis.

Detailed description: The primary objective is to describe on an exploratory basis the association between the type of proteomic profile from cerebrospinal fluid (CSF) microvesicles (from unsupervised bioinformatics analysis) and CSF cytology analysis (positive, negative, equivocal) in breast cancer patients with suspected leptomeningeal metastases, on initial CSF samples (hereafter referred to as initial proteomic profile and initial cytology).

Eligibility criteria: Inclusion Criteria:

* Patient with histologically proven breast cancer;
* Patient with suspected metastatic leptomeningeal involvement;
* Age ≥ 18 ans ;
* WHO performance status ≤ 2 ;
* Affiliation to the National Social Security System ;
* With informed and signed consent

Exclusion Criteria:

* History of another cancer than the one for which the patient is referred;
* Contraindication to lumbar puncture or cerebrospinal MRI
* Pregnant or breastfeeding woman

Primary outcomes:
measure: CSF protein composition
timeFrame: 36 months
measure: cytological analysis of the CSF
timeFrame: 36 months
Secondary outcomes:
Other outcomes:
Locations:
city: Lille
country: France
facility: Centre Oscar Lambret
state: Hauts de France
Study officials:
affiliation: Centre Oscar Lambret
name: Claire Cheymol, MD
role: PRINCIPAL_INVESTIGATOR
References: